<DOC>
	<DOC>NCT00460603</DOC>
	<brief_summary>To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.</brief_summary>
	<brief_title>Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>(Phase 1) Patients with any solid/GI tumor who have had no more than 1 previous chemotherapy for greater than 3 months prior to enrollment (Phase 2) Patients with locally advanced or metastatic colorectal cancer (CRC) previously untreated with any systemic therapy. Patients treated with adjuvant chemotherapy (with radiation) will be eligible if last treatment was &gt; 12 months prior to enrollment, Patients must have measurable disease by RECIST and if any history of hypertension, it must be controlled with medication. Prior system therapy for advanced CRC (Ph 2 portion only) Prior treatment with antiangiogenesis agent such as bevacizumab or VEGF inhibitors. Prior irradiation of greater than 25% of bone marrow (whole pelvis = 25%) Prior radiation, major surgery, or investigational agent within 4 weeks of study entry except palliative radiotherapy to nontarget, metastatic lesions. Minor surgeries should be completed &gt; 2 weeks of enrollment and be fully recovered from any procedure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>GI neoplasms (phase 1)</keyword>
</DOC>